Inhibitors of NF-kappaB activation

Details Inhibitors of NF-kappaB activation Inhibitors of NF-kappaB activation

2003-10-08

2008-08-19

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07414026

ABSTRACT:
The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-κB) activating pathway useful in the treatment of NF-κB related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than IκB.

REFERENCES:
patent: 4186183 (1980-01-01), Steck et al.
patent: 4217344 (1980-08-01), Vanlerberghe et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4261975 (1981-04-01), Fullerton et al.
patent: 4485054 (1984-11-01), Mezei et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4774085 (1988-09-01), Fidler
patent: 4797368 (1989-01-01), Carter et al.
patent: 4837028 (1989-06-01), Allen
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: WO 91/16024 (1991-10-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 97/37016 (1997-10-01), None
patent: WO 99/57133 (1999-11-01), None
Song et al., The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kB activation, Proc. Natl. Acad. Sci. USA, 1996, vol. 93, p. 6721-6725.
Jaattela et al., A20 zzzzzinc finger protein inhibits YNF and IL-1 signaling, The Journal of Immunology, 1996, 156, p. 1166-1173.
Ferran et al., A29 inhibits NF-kB activation in endothelial cells without sesnsitizing to tumor necrosis factor-mediated apoptosis, Blood, 1998, vol. 91, p. 2249-2258.
Heyninck et al., The zinck finger protein A20 inhibits TNF-induced NF-kB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kB-inhibiting protein ABIN, The Journal of Cell Biology, 1999, vol. 145, p. 1471-1482.
De Valck et al., “A20, an inhibitor of cell death, self-associates by its zinc finger domain,” 384 FEBS Letters 61-64 (1996).
Fukushi, M., Homosapiens mRNA for HIV-1, Nef-associated factor 1 beta (Naf1 bets),: EMHUM Database Entry HSA011896, Accession No. AJ011896, Oct. 14, 1998, XP002124741.
Fukushi, M., et al., “NAF1 alpha protein (KIAA0113 protein),” TREMBL Database Entry A15025, Accession No. Q15025, Nov. 1, 1996, XP02124740.
Hendrick, B.D., et al., “An X-linked homologue of the autosomal imprinted gene NF127 escapes X chromosome inactivation,” EMHUM Database Entry HS4131510; Accession No. U41315, May 19, 1996, XP002125387.
Heyninck et al., “The Zinc Finger Protein A20 Inhibits TNF-induced NF-kB-dependent Gene Exp[ression by interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-kB-inhibiting Protein ABIN,” 145 The Journal of Cell Biology 1471-1482 (1999).
Miyajima, N., et al., “Human mRNA for KIAA 0133 gene, partial coding sequence,” EMHUM Databse Entry HSORFA2, Accession No. D30755, May 21, 1994, XP002124739.
Nomura et al., “mRNA for ORF, partial CDS (fragment),” TRHUM Database Entry Q15025; Nov. 1, 1996, Accession No. Q15025, XP002080989.
Song et al., “The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kB activation,” 93 Proc. Natl. Acad. Sci. USA 6721-6725 (1996).
Yen, R.W.C., et al., “DNA-methyltransferase,” SWISSPROT Database Entry MTDM—Human; May 1, 1992, Accession No. P26358, XP002080990.
PCT International Search Report, PCT/BE99/00055, dated Dec. 31, 1999 (9 pages).
PCT International Preliminary Examination Report, PCT/BE99/00055, dated Aug. 10, 2000.
Yamamoto et al., “Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer,” 107(2) J. Clin. Invest. 135-142 (Jan. 2001).
Ghosh, et al., “Missing Pieces in the NF-kappaB Puzzle,” 109 Cell S81-S96 (Apr. 2002).
Baldwin, A.S., “The transcription factor NF-kappaB and human disease,” 107(1) J. Clin. Invest. 3-6 (Jan. 2001).
Ngo et al., “Computational Complexity, Protein Structure Prediction and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure, Merz et al. ed., pp. 14-16 (1994).
Zhang, et al., “Environment-dependent residue contact energies for proteins,” 97(6) Proc. Natl. Sci. 2550-2555 (Mar. 2000).
Fukushi et al., (Nov. 1, 1996) Acc. No. Q15025, SPTREMBL—17 database, GenCore Version 4.5, Accessed May 8, 2002.
Gupta, et al. (Mar. 1, 2001) Acc. No. Q9H1J3, SPTREMBL—17, GenCore Version 4.5, Accessed May 8, 2002.
Heyninck, K., et al., “Structure-function analysis of the A20-binding inhibitor of NF-κB activation, ABIN-1,” 536 FEBS Letters 135-140 (2003).
Wullaert et al., LIND/ABIN-3 Is a Novel Lipopolysaccharide-inducible Inhibitor of NF-kappaB Activation, The Journal of Biological Chemistry, Jan. 5, 2007, pp. 81-90, vol. 282, No. 1.

Affiliated with

Also associated with

Rating

Inhibitors of NF-kappaB activation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of NF-kappaB activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of NF-kappaB activation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3997716